However, since the hypoxic microenvironment and HIF-1α overexpression in RA synovium are similar to those in solid tumors, these HIF-1α inhibitors are expected to become a new strategy for the treatment of RA. This evidence concerns the gene HIF1A and rheumatoid arthritis.